ICI 141292

Known as: ICI 141,292, ICI-141,292 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1983-1989
01219831989

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
This randomized, double-blind, crossover study in 10 healthy male volunteers compared four single oral doses of ICI 141,292… (More)
Is this relevant?
1990
1990
The pharmacokinetics of ICI 141,292 (epanolol) were studied over 3 days after a single oral 200 mg dose and then over 24 h after… (More)
  • table 1
  • figure 2
Is this relevant?
1989
1989
Single doses of epanolol (ICI 141,292) were administered to 12 healthy young male volunteers in a randomised crossover study… (More)
Is this relevant?
1987
1987
ICI 141,292 is a new beta 1-adrenoceptor blocking drug. The beta 1-adrenoceptor antagonistic effect of ICI 141,292 was examined… (More)
Is this relevant?
1986
1986
The beta-adrenoceptor blocking properties and cardioselectivity of ICI 141, 292 were investigated in healthy male subjects. Seven… (More)
Is this relevant?
1986
1986
ICI 141,292 is a β-blocker with β1-selective partial agonist activity. To study its cardioselectivity in humans, comparable… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
1984
1984
The objective of this placebo controlled double-blind multicentre (six centres) trial was to investigate the safety and efficacy… (More)
Is this relevant?
1984
1984
The cardioselective beta-adrenergic blocking drμg Visacor (ICI 141,292) was dosed to six beagle dogs in a randomized cross-over… (More)
  • table I
  • figure 1
  • table II
  • table III
  • table IV
Is this relevant?
1983
1983
Six groups of four dogs were studied under pentobarbital anesthesia. Plasma levels of free fatty acids (FFA), glucose, insulin… (More)
Is this relevant?